 |
6 Diseases |  |
125 Trials |
|
125 Trials |  |
2571 News |  |
| «12...1011121314151617181920...3334» |
- Vectibix (panitumumab) / Amgen, Takeda, Lumakras (sotorasib) / Amgen
Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator's choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2277;
P3
The objective of the current study is to evaluate whether the combination of sotorasib and panitumumab is superior to standard of care trifluridine/tipiracil or regorafenib in the setting of chemorefractory mCRC...Patients must have received and progressed or experienced disease recurrence on or after fluoropyrimidine, irinotecan, and oxaliplatin given for metastatic disease unless ineligible in the opinion of the investigator...Key secondary endpoints include overall survival and objective response. Global enrollment is ongoing.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Talzenna (talazoparib) / Pfizer
Tumor organoids from multifocal metastatic colorectal cancers for personalized oncology (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_1975;
Ex vivo drug vulnerabilities from the living biobank are currently being used as a reference basis for an interventional phase II umbrella clinical study for patients with advanced CRC. Conclusions In conclusion, PDOs from multifocal liver metastases model pharmacogenomic heterogeneity of advanced colorectal cancers and have strong potential for personalized oncology.
- |||| Lonsurf (trifluridine/tipiracil) / Otsuka, Opdivo (nivolumab) / BMS
New P2 trial: LOGICAN: Oxaliplatin (clinicaltrials.gov) - Jul 27, 2022
P2, N=118, Not yet recruiting, Sponsor: UNICANCER
- Elunate (fruquintinib) / Hutchmed
FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer (7.2.F - Fécamp Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1491;
P3
F was well tolerated, with a safety profile consistent with the established profile for F monotherapy. FRESCO-2 results are consistent with FRESCO and should support a new treatment option in refractory mCRC.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Tevimbra (tislelizumab-jsgr) / BeiGene, Avastin (bevacizumab) / Roche
Enrollment open: TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2022
P2, N=25, Recruiting, Sponsor: Fujian Cancer Hospital
FRESCO-2 results are consistent with FRESCO and should support a new treatment option in refractory mCRC. Not yet recruiting --> Recruiting
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment open: Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 23, 2022
P2, N=153, Recruiting, Sponsor: Dominik Paul Modest
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
Enrollment closed: PULSE: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Jul 23, 2022
P2, N=120, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical: I think of these drugs still as important tools as maintenance systemic therapies. PFS/OS more meaningful goals. TAS-102➕BEV also now in the guidelines. This is also a good reference. @TheLancetOncol https://t.co/LOavzudJMA Also our observation of chemo induced neutropenia👇🏾 (Twitter) - Jul 23, 2022
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Paging #MedTwitter GI colleagues 👉🏼 What is the ORR of regorafenib and Lonsurf in CRC & is there a good reference for this ? @cancerassassin1 @MPishvaian @ArndtVogel @BenWestphalen @Benjohnson1112 (Twitter) - Jul 23, 2022
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Vectibix (panitumumab) / Amgen
New P2 trial: Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial (clinicaltrials.gov) - Jul 21, 2022
P2, N=68, Completed, Sponsor: University of Campania "Luigi Vanvitelli"
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date, Metastases: TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jul 18, 2022
P2, N=28, Recruiting, Sponsor: The University of Hong Kong
Recruiting --> Active, not recruiting Trial completion date: Mar 2026 --> Nov 2023 | Trial primary completion date: Mar 2022 --> May 2023
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal, Real-world evidence: Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England. (Pubmed Central) - Jul 15, 2022
Our results support the publication of national outcome data. If these results are confirmed on a larger cohort, it would support the reappraisal of certain drugs and provide further evidence to clinicians and patients when deciding the best treatment.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Retrospective data, Journal: Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. (Pubmed Central) - Jul 13, 2022
If these results are confirmed on a larger cohort, it would support the reappraisal of certain drugs and provide further evidence to clinicians and patients when deciding the best treatment. Treatment with FTD/TPI produced a survival benefit, relative to placebo, regardless of KRAS codon 12 or 13 mutation status in patients with previously treated mCRC.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer (clinicaltrials.gov) - Jul 11, 2022
P2, N=27, Recruiting, Sponsor: Providence Health & Services
Treatment with FTD/TPI produced a survival benefit, relative to placebo, regardless of KRAS codon 12 or 13 mutation status in patients with previously treated mCRC. Not yet recruiting --> Recruiting
- |||||| Lonsurf (trifluridine/tipiracil) / Otsuka, futuximab/modotuximab (S95026) / Servier
Enrollment open, Combination therapy, Metastases: COLSTAR: Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 8, 2022
P3, N=500, Recruiting, Sponsor: Institut de Recherches Internationales Servier
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Oxaliplatin and Irinotecan were turn of the Century not 60s Cetuximab - late 2000's All three are predominantly used in GI cancers more than anything else. Lonsurf later still although not a major breakthrough. (Twitter) - Jul 3, 2022
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer (clinicaltrials.gov) - Jul 1, 2022
P2, N=27, Not yet recruiting, Sponsor: Providence Health & Services
Not yet recruiting --> Recruiting Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Apr 2022 --> Oct 2024
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Mekinist (trametinib) / Novartis
Proud of @cityofhope fellow #DrJeremyChuang (is he on @Twitter, @arafflemd?) who authored this paper w @jgong15 @CedarsSinaiMed & GI program lead @mgfakih evaluting #trametinib w #TAS102 in chemoR RASm mCRC. @stacywgray @DrRaviSalgia @cityofhopeoc @COHMedOnc (Twitter) - Jun 29, 2022
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal: Long-term survivors of metastatic colorectal cancer treated with trifluridine/tipiracil. (Pubmed Central) - Jun 28, 2022
Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Apr 2022 --> Oct 2024 No abstract available
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
What is the roles of Lonsurf (FTD/TPI) for the treatment of CRC/GC patients? (Room C) - Jun 28, 2022 - Abstract #KSMO2022KSMO_156;
No abstract available Sponsored by JEIL
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
The role of FTD/TPI in treatment of patients with mGC (Room C) - Jun 28, 2022 - Abstract #KSMO2022KSMO_34;
Sponsored by JEIL Sponsored by JEIL
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
The role of FTD/TPI in treatment of patients with mCRC (Room C) - Jun 28, 2022 - Abstract #KSMO2022KSMO_33;
Sponsored by JEIL Sponsored by JEIL
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Observational data, Retrospective data, Journal, Real-world evidence: Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study. (Pubmed Central) - Jun 23, 2022
Sponsored by JEIL The observed OS in this study for HER2-positive G/GEJ cancer was shorter than that reported previously, suggesting that the effectiveness of nivolumab, irinotecan, or FTD/TPI as 3L + therapy may be limited.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Enrollment open, Metastases: TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (clinicaltrials.gov) - Jun 23, 2022
P2, N=42, Recruiting, Sponsor: Roswell Park Cancer Institute
The observed OS in this study for HER2-positive G/GEJ cancer was shorter than that reported previously, suggesting that the effectiveness of nivolumab, irinotecan, or FTD/TPI as 3L + therapy may be limited. Active, not recruiting --> Recruiting
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
A very interesting poster will be presented @ESMOWorldGI by @giconnectInfo expert Dr. Bekaii-Saab, @GIcancerDoc! #regorafenib dose optimization vs supportive care and TAS-102 in metastatic/relapsed #CRC. ➡️Poster:44, 2 July https://t.co/D59XBF2gRM #MedEd #WCGIC2022 (Twitter) - Jun 19, 2022
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial primary completion date: Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Jun 13, 2022
P2, N=45, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2022 --> Dec 2023
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Journal: Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. (Pubmed Central) - Jun 10, 2022
Trial primary completion date: Dec 2022 --> Dec 2023 In crossover use of TFTD with/without Bev and regorafenib, both agents showed similar efficacy in terms of the conventional parameters, but the differences observed in the TGR and TGK might suggest some influence of prior regorafenib treatment on the efficacy of subsequent TFTD therapy, and vice versa.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, P2 data, Journal: Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. (Pubmed Central) - Jun 9, 2022
In crossover use of TFTD with/without Bev and regorafenib, both agents showed similar efficacy in terms of the conventional parameters, but the differences observed in the TGR and TGK might suggest some influence of prior regorafenib treatment on the efficacy of subsequent TFTD therapy, and vice versa. Trifluridine/tipiracil monotherapy is feasible and shows modest activity in patients with refractory esophageal squamous cell carcinoma.
- || Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer, Lumakras (sotorasib) / Amgen
Trial completion date: CodeBreak 300: Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (clinicaltrials.gov) - Jun 8, 2022
P3, N=153, Recruiting, Sponsor: Amgen
Trifluridine/tipiracil monotherapy is feasible and shows modest activity in patients with refractory esophageal squamous cell carcinoma. Trial completion date: Dec 2023 --> Mar 2024
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Retrospective data, Journal: The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. (Pubmed Central) - Jun 8, 2022
Trial completion date: Dec 2023 --> Mar 2024 The development of chemotherapy including late-line treatments could improve the prognosis of mCRC patients.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Observational data, Journal: An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer. (Pubmed Central) - Jun 8, 2022
Our results suggested that TAS-102 had better oncologic outcomes than REG in patients with mCRC, especially in combination. Further prospective trials are warranted to confirm our results.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open, Minimal residual disease, Circulating tumor DNA: TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov) - Jun 8, 2022
P2, N=15, Recruiting, Sponsor: M.D. Anderson Cancer Center
Further prospective trials are warranted to confirm our results. Not yet recruiting --> Recruiting
- || Xpovio (selinexor) / Karyopharm
Enrollment closed, Trial primary completion date, Metastases: A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations (clinicaltrials.gov) - Jun 6, 2022
P2, N=78, Active, not recruiting, Sponsor: Karyopharm Therapeutics Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Jul 2022
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Clinical, Journal, HEOR, Combination therapy: Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. (Pubmed Central) - May 31, 2022
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Jul 2022 Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line for mCRC patients who were not candidates for combination with cytotoxic chemotherapies.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Observational data, Journal, Real-world evidence: Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". (Pubmed Central) - May 31, 2022
In a matched population, PFS was significantly longer in the FTD/TPI group. Despite a limited number of patients, clinical outcomes seemed similar in patients treated with the T/R or R/T sequence.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal, HEOR: Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). (Pubmed Central) - May 31, 2022
The QoL deterioration in "poor responders" is likely due to disease progression. The strong association between worse baseline QoL and shorter survival suggests that clinicians should take QoL into account when determining prognosis and treatment strategy for individual patients.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
#Otsuka World-Wide Sales for #LONSURF was 13548m JPY in Q1 2022 https://t.co/vI4kCM8zeg (Twitter) - May 31, 2022
- Lonsurf (trifluridine/tipiracil) / Otsuka
Phase classification, Minimal residual disease, Circulating tumor DNA: Study of CtDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas (clinicaltrials.gov) - May 30, 2022
P1, N=22, Recruiting, Sponsor: University of California, Irvine
The strong association between worse baseline QoL and shorter survival suggests that clinicians should take QoL into account when determining prognosis and treatment strategy for individual patients. Phase classification: P2 --> P1
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Journal: First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. (Pubmed Central) - May 29, 2022
P2
Phase classification: P2 --> P1 TT-B is a promising therapeutic regimen in mCRC patients ineligible for intensive chemotherapy.
- |||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial primary completion date, Combination therapy, Metastases: SOLSTICE: Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (clinicaltrials.gov) - May 26, 2022
P3, N=856, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
TT-B is a promising therapeutic regimen in mCRC patients ineligible for intensive chemotherapy. Trial primary completion date: Sep 2022 --> Jun 2021
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial primary completion date, Combination therapy, Metastases: Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov) - May 26, 2022
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2022 --> Jun 2021 Trial primary completion date: May 2023 --> Aug 2021
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, P1 data, Clinical Trial,Phase I, Journal, Combination therapy: A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. (Pubmed Central) - May 25, 2022
There was no G5 TRAE. The combination of TASIRI showed encouraging clinical activity with a meaningful improvement in PFS-6 compared to historic controls.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Biomarker, Journal: The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. (Pubmed Central) - May 19, 2022
Our study validates the improved trifluridine/tipiracil efficacy in patients with GPC in comparison with PPC while maintaining a well-tolerated safety profile. Indolent disease, low tumour burden and the absence of liver metastasis were shown to be good prognosis factors influencing sustained response to trifluridine/tipiracil.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal, Combination therapy: An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer. (Pubmed Central) - May 18, 2022
The RP2D of FTD/TPI combined with irinotecan was determined to be Level 1B; this level was associated with manageable hematologic toxicities and feasible non-hematologic toxicities. Further evaluation of the efficacy of RP2D treatment is necessary.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal: Trifluridine induces HUVECs senescence by inhibiting mTOR-dependent autophagy. (Pubmed Central) - May 18, 2022
Trifluridine, a key component of trifluridine/tipiracil, is a potential anti-cancer drug that can act effectively on refractory metastatic colorectal cancer...Chloroquine diphosphate salt and rapamycin were used to detect the effect of trifluridine on autophagy flux and mTOR signaling pathway...In addition, also trifluridine induced cellular senescence by inhibiting autophagy and was closely related to the activation of the mTOR signaling pathway, therefore, we believe that trifluridine may be an effective mTOR activator. The findings also provide a new strategy for establishing autophagy or aging models, as well as a new theoretical basis for the use of trifluridine in clinical treatment.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (clinicaltrials.gov) - May 18, 2022
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
The findings also provide a new strategy for establishing autophagy or aging models, as well as a new theoretical basis for the use of trifluridine in clinical treatment. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date: FIERCE: TAS-102 with Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer (clinicaltrials.gov) - May 12, 2022
P1b, N=18, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer (Auditorium B; Level 0) - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_506;
Disease control rate (DCR) and progression-free survival (PFS) as measures of the efficacy of FTD/TPI plus BEV were compared between 2 groups with high and low levels of each marker. Conclusions Plasma levels of HGF and IL-8 at baseline may serve as a predictor for better DCR and PFS of FTD/TPI plus BEV as second-line treatment in pts with mCRC, although further studies are warranted.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: pooled analysis of PRECONNECT and TALLISUR studies (Auditorium B; Level 0) - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_505;
Conclusions In this pooled analysis, QoL and ECOG PS were maintained in most patients with mCRC receiving treatment with FTD/TPI. These data also show an association between time to ECOG PS deterioration and change in QLQ-C30 GHS score over time.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
A multicenter exploratory analysis of the possible predictive factors for trifluridine/tipiracil in refractory metastatic colorectal cancer () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_353;
Conclusions Although lacking statistical significance, our results support that patients with more indolent clinical course of the disease tend to derive somewhat greater survival benefit from trifluridine/tipiracil. Furthermore, the greatest benefit was demonstrated in older patients and with best performance status regardless of tumor characteristics or previous therapy.